Summary Of Significant Accounting Policies (Summary Of Net Revenues By Product Category) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended
Mar. 31, 2012	Mar. 31, 2011
Summary Of Significant Accounting Policies [Abstract]
Respiratory and other chronic therapies	$ 449,544	$ 386,020
DME, infusion and enteral therapies	51,334	45,547
Total	$ 500,878	$ 431,567

Aggregate revenue recognized during the period (derived from goods sold, services rendered, insurance premiums, or other activities that constitute an entity's earning process). For financial services companies, also includes investment and interest income, and sales and trading gains.

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 5

-Section 03

-Paragraph 1

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Name:	us-gaap_Revenues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration